Publications by authors named "Zoe Ygj Van Lierop"
Article Synopsis
- Serum neurofilament light (sNfL) serves as a biomarker for neuro-axonal damage in multiple sclerosis (MS) but its clinical usage is still limited; this study assessed how its implementation affects clinical decisions at the MS Center Amsterdam.
- Over the study period (August 2021-December 2022), sNfL was evaluated in various contexts, with a notable change in clinical decisions in 19.3% of cases, especially when assessing new symptoms or when higher sNfL levels were present.
- The findings suggest that integrating sNfL into clinical practice improved decision-making certainty and potentially adjusted expectations regarding MRI activity, indicating its potential value in patient care while calling for further research
Background: Extended interval dosing (EID) of natalizumab is a promising strategy to optimise treatment in multiple sclerosis (MS). Personalised EID by therapeutic drug monitoring can enable further extension of treatment intervals.
Methods: The NEXT-MS trial is an investigator-initiated prospective phase IV non-randomised study.
Background: There is a need in Relapsing-Remitting Multiple Sclerosis (RRMS) treatment for biomarkers that monitor neuroinflammation, neurodegeneration, treatment response, and disease progression despite treatment.
Objective: To assess the value of serum glial fibrillary acidic protein (sGFAP) as a biomarker for clinical disease progression and brain volume measurements in natalizumab-treated RRMS patients.
Methods: sGFAP and neurofilament light (sNfL) were measured in an observational cohort of natalizumab-treated RRMS patients at baseline, +3, +12, and +24 months and at the last sample follow-up (median 5.
Article Synopsis
- Patients with relapsing-remitting multiple sclerosis (RRMS) often experience significant long-term neurodegeneration despite effective treatments.
- The study evaluated the predictive value of serum neurofilament-light (sNfL) and serum contactin-1 (sCNTN1) in assessing neurodegeneration using MRI in RRMS patients treated with natalizumab over several years.
- Results showed that sNfL levels after the first year of treatment were associated with brain atrophy metrics, while sCNTN1 levels did not demonstrate a clear predictive value.
In this observational study, 159 patients with multiple sclerosis received personalized dosing of ocrelizumab incentivized by the COVID-19 pandemic. Re-dosing was scheduled when CD19 B-cell count was ⩾10 cells/µL (starting 24 weeks after the previous dose, repeated 4-weekly). Median interval until re-dosing or last B-cell count was 34 [30-38] weeks.
View Article and Find Full Text PDFBackground: Natalizumab treatment provides a model for non-inflammation-induced disease progression in multiple sclerosis (MS).
Objective: To study serum contactin-1 (sCNTN1) as a novel biomarker for disease progression in natalizumab-treated relapsing-remitting MS (RRMS) patients.
Methods: Eighty-nine natalizumab-treated RRMS patients with minimum follow-up of 3 years were included.